Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shugan Hewei granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine and the Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the treatment of refractory gastroesophageal reflux disease (rGERD), specifically targeting patients who present with the TCM syndrome pattern of qi stagnation and phlegm obstruction. The formulation is designed to 'soothe the liver' and 'harmonize the stomach,' which involves regulating gastrointestinal motility and improving esophageal clearance. In clinical studies, it has been evaluated as a therapeutic alternative or adjunct to proton pump inhibitors (PPIs) such as rabeprazole for patients who do not respond adequately to standard acid-suppression therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shugan Hewei granules.